4D Molecular Therapeutics (FDMT) Operating Expenses (2020 - 2026)

4D Molecular Therapeutics (FDMT) has reported Operating Expenses for 7 consecutive years, with $76.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Expenses rose 42.94% year-over-year to $76.7 million; the TTM figure through Mar 2026 stood at $267.8 million (up 31.69% YoY), while the FY2025 annual figure was $244.8 million, up 30.27% from the prior year.
• Operating Expenses rose to $76.7 million in Q1 2026 per FDMT's latest filing, from $70.4 million in the prior quarter.
• Across five years, Operating Expenses topped out at $76.7 million in Q1 2026 and bottomed at $27.0 million in Q3 2022.
• Historically, Operating Expenses has averaged $44.5 million across 5 years, with a median of $38.2 million in 2024.
• Annual changes were most pronounced in 2023 — Operating Expenses rose 10.12% — and 2024, when it surged 53.19%.
• 4D Molecular Therapeutics' Operating Expenses stood at $30.0 million in 2022, then rose by 22.24% to $36.6 million in 2023, then soared by 53.19% to $56.1 million in 2024, then advanced by 25.41% to $70.4 million in 2025, then grew by 8.94% to $76.7 million in 2026.
• Business Quant data shows FDMT's Operating Expenses at $76.7 million in Q1 2026, $70.4 million in Q4 2025, and $61.3 million in Q3 2025.